Meeting
2018 ASCO Annual Meeting
Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.
Authors
A. Oliver Sartor
Tulane Medical School, New Orleans, LA
A. Oliver Sartor , Celestia S. Higano , Matthew R. Cooperberg , Nicholas J. Vogelzang , Shaker R. Dakhil , Christopher Michael Pieczonka , Jeff Vacirca , Raoul S Concepcion , Ronald F Tutrone , Luke T. Nordquist , Carl A Olsson , David F. Penson , Ian Schnadig , James L. Bailen , Bryan Mehlhaff , Nancy N. Chang , Nadeem Anwar Sheikh , Bruce Brown , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01306890
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5041)
DOI
10.1200/JCO.2018.36.15_suppl.5041
Abstract #
5041
Poster Bd #
268
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Celestia S. Higano
Poster
2016 Genitourinary Cancers Symposium
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.
First Author: Celestia S. Higano
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco